Drugs

Picture this: you’re filling/verifying prescriptions and you get that all too familiar pop-up that notifies you of a QT-prolongation interaction . . . how should you approach this?

Effects believed to rival hypertension medications.

Can you tell which statement about Litfulo (ritlecitinib), the new prescription drug for treatment of severe alopecia areata, is false?

National Advisory Committee on Immunization issues updated recommendations for use of Novavax’s Nuvaxovid XBB.1.5 COVID-19 vaccine.

The U.S. Food and Drug Administration approved a label change requested by drugmaker Novo Nordisk that expands the use of semaglutide.

A Canadian Paediatric Society practice point document addresses the use and interpretation of pharmacogenetic testing for psychoactive medications in children.

Many worry, rightly, that they’ll regain weight and revert to old habits. In clinical trials, patients who paused the drugs put back on most of the weight they lost.

The new drug Litfulo (ritlecitinib) has reached the Canadian market, while baricitinib (Olumiant) is now approved for alopecia areata and in a new higher-strength tablet.